Aerami Therapeutics to Present New Lung Deposition Modeling Data for AER-901, in Development for Pulmonary Hypertension, at the American Thoracic Society 2024 International Conference
One presentation will feature new lung deposition modeling data comparing the deposition of AER-901 to that of a hypothetical dry powder inhaled (DPI)-imatinib in subjects with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH), as well as healthy volunteers.
- One presentation will feature new lung deposition modeling data comparing the deposition of AER-901 to that of a hypothetical dry powder inhaled (DPI)-imatinib in subjects with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH), as well as healthy volunteers.
- These modeling data were generated by FLUIDDA, Inc., using their proprietary Functional Respiratory Imaging (FRI) And Rapid Deposition Analysis (RDA) platforms.
- In addition, the unique and innovative design of the “uniPHied” platform Phase 2 trial will be presented, demonstrating the optionality to expeditiously evaluate AER-901 in multiple pulmonary hypertension cohorts (initially PH-ILD and PAH).
- "We are excited to present new lung deposition modeling data that we believe strongly support the differentiation of AER-901 and its potential to reverse the vascular remodeling process central to multiple forms of pulmonary hypertension," said Gary Burgess, MD, Chief Medical Officer of Aerami.